Short Bowel Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SHR001 MIFTS: 52	Short Bowel Syndrome Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Short Bowel Syndrome

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁵³ ⁴³ ¹⁴ ⁷¹ ³³

Short Gut Syndrome ¹¹ ³³

Secondary Short Bowel Syndrome ³³

Acquired Short Bowel Syndrome ¹¹

Short Bowel Nos ³³

Characteristics:

Prevelance:

1-9/100000 (Europe) ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Genetic diseases Fetal diseases
Anatomical: Gastrointestinal diseases Liver diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the digestive system

Diseases of small intestine

Intestinal malabsorption or protein-losing enteropathy

Intestinal malabsorption

Short bowel syndrome

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹¹ DOID:10605

MeSH ⁴³ D012778

NCIt ⁴⁹ C99059

SNOMED-CT ⁶⁸ 204768009

MESH via Orphanet ⁴⁴ D012778

UMLS via Orphanet ⁷² C0036992

Orphanet ⁵⁸ ORPHA104008

ICD11 ³³ 780637678

UMLS ⁷¹ C0036992

Sources

Summaries for Short Bowel Syndrome

GARD: ¹⁹ Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of Short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue.

MalaCards based summary: Short Bowel Syndrome, also known as short gut syndrome, is related to congenital short bowel syndrome and intestinal pseudo-obstruction, and has symptoms including pain, postoperative and postoperative nausea and vomiting. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors). The drugs Ursodeoxycholic acid and Plasminogen have been mentioned in the context of this disorder. Affiliated tissues include small intestine, kidney and liver, and related phenotypes are homeostasis/metabolism and nervous system

Orphanet: ⁵⁸ Short bowel syndrome is an intestinal failure due to either a congenital defect, intestinal infarction or extensive surgical resection of the intestinal tract that results in a functional small intestine of less than 200cm in length and is characterized by diarrhea, nutrient malabsoption, bowel dilation and dysmobility.

Disease Ontology: ¹¹ An intestinal disease that is characterized by a reduced ability to absorb nutrients due to the physical loss or the loss of function of a portion of the small and/or large intestine.

Wikipedia: ⁷⁵ Short bowel syndrome (SBS, or simply short gut) is a rare malabsorption disorder caused by a lack of... more...

Sources

Related Diseases for Short Bowel Syndrome

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome	Primary Short Bowel Syndrome
Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)

#	Related Disease	Score	Top Affiliating Genes
1	congenital short bowel syndrome	33.2	FLNA CLMP
2	intestinal pseudo-obstruction	32.3	SST FLNA CLMP
3	volvulus of midgut	32.2	PYY GCG CCK
4	cholelithiasis	30.8	SST GAST CCK
5	ileus	30.5	SLC9A3 IL6 GLP2R GHRL
6	bone disease	30.5	IL6 IGF1 HGF FLNA
7	secretory diarrhea	30.4	SST SLC9A3 GAST
8	acute kidney failure	30.3	SLC9A3 IL6 HGF
9	meckel diverticulum	30.3	SST SLC15A1 GCG GAST
10	glucagonoma	30.3	SST GAST
11	carcinoid tumors, intestinal	30.2	SST GAST
12	hyperinsulinemic hypoglycemia	30.2	SST GCG GAST
13	gallbladder disease	30.2	SST PYY IL6 CCK
14	obstructive jaundice	30.2	TTR SST CCK
15	diarrhea	30.1	TTR SST SLC9A3 PYY NTS IL6
16	nutritional deficiency disease	30.1	TTR PYY IL6 IGF1 GHRL GH1
17	duodenal obstruction	30.1	SST CCK
18	colonic benign neoplasm	30.1	IL6 IGF1 GAST EGF
19	carcinoid syndrome	30.0	SST PYY NTS IGF1
20	esophagitis	30.0	NTS IL6 GAST
21	corneal ulcer	30.0	IL6 FGF7 EGF
22	gastroduodenal crohn's disease	30.0	GAST CCK
23	pancreatitis	29.9	SST IL6 GCG CCK
24	peptic ulcer disease	29.8	SST IL6 GHRL GAST CCK
25	fatty liver disease	29.8	IL6 IGF1 GHRL GCG
26	hepatic encephalopathy	29.8	TTR SST IL6
27	insulin-like growth factor i	29.7	SST IL6 IGF1 GHRL GH1 EGF
28	gastroparesis	29.7	SST GHRL GAST CCK
29	leptin deficiency or dysfunction	29.7	PYY IL6 IGF1 GHRL GCG CCK
30	hypoglycemia	29.7	SST IGF1 GHRL GH1 GCG GAST
31	mucositis	29.6	GLP2R GHRL GCG FGF7 EGF
32	hyperinsulinism	29.6	SST IGF1 GHRL GH1 GCG
33	chronic kidney disease	29.6	TTR IL6 IGF1 HGF GHRL
34	liver cirrhosis	29.5	TTR SST IL6 HGF GCG
35	protein-energy malnutrition	29.5	TTR IL6 IGF1 CCK
36	bowel dysfunction	29.4	PYY IL6 GLP2R GHRL GCG FGF7
37	kidney disease	29.4	TTR IL6 IGF1 HGF GHRL FGF7
38	arteriosclerosis	29.4	TTR IL6 HGF GHRL
39	dumping syndrome	29.3	SST PYY NTS GHRL GCG GAST
40	type 1 diabetes mellitus	29.3	SST IL6 IGF1 GHRL GH1 GCG
41	conn's syndrome	29.3	SST IL6 IGF1 GHRL GH1 GCG
42	cystic fibrosis	29.3	SLC9A3 NTS IL6 IGF1 EGF CCK
43	neuroendocrine tumor	29.2	SST NTS IGF1 GHRL GCG GAST
44	hypothyroidism	29.2	TTR SST IGF1 GH1
45	osteoporosis	29.2	IL6 IGF1 HGF GHRL GH1 EGF
46	celiac disease 1	29.1	PYY IL6 IGF1 GHRL GCG GAST
47	inflammatory bowel disease	29.0	SST SLC9A3 SLC15A1 PYY NTS IL6
48	deficiency anemia	29.0	TTR IL6 IGF1 GHRL GH1 GAST
49	body mass index quantitative trait locus 11	28.8	PYY NTS IL6 IGF1 GHRL GH1
50	intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked	11.5

Graphical network of the top 20 diseases related to Short Bowel Syndrome:

Sources

Symptoms & Phenotypes for Short Bowel Syndrome

UMLS symptoms related to Short Bowel Syndrome:

pain, postoperative; postoperative nausea and vomiting

GenomeRNAi Phenotypes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.21	AOC1 CCK CLMP EGF FGF7 FLNA
2	no effect	GR00402-S-2	10.21	AOC1 CCK CLMP EGF FGF7 FLNA

MGI Mouse Phenotypes related to Short Bowel Syndrome:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.19	AOC1 CCK CLMP FGF7 FLNA GAST
2	nervous system	MP:0003631	10.14	AOC1 CCK FGF7 FLNA GH1 HGF
3	renal/urinary system	MP:0005367	10.02	CCK CLMP FGF7 GCG GH1 IGF1
4	growth/size/body region	MP:0005378	9.97	AOC1 CLMP EGF FLNA GCG GH1
5	adipose tissue	MP:0005375	9.92	GH1 GHRL GLP2R IGF1 IL6 NTS
6	endocrine/exocrine gland	MP:0005379	9.7	AOC1 CCK EGF GAST GCG GH1
7	digestive/alimentary	MP:0005381	9.4	CLMP EGF FLNA GAST GCG GHRL

Sources

Drugs & Therapeutics for Short Bowel Syndrome

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ursodeoxycholic acid

Approved, Investigational

Phase 4

128-13-2

31401

Plasminogen

Approved

Phase 4

9001-91-6

Carbamide peroxide

Approved

Phase 4

124-43-6

Apixaban

Approved

Phase 4

503612-47-3

10182969

Aspartic acid

Approved, Nutraceutical

Phase 4

56-84-8

5960

L-Glutamine

Approved, Investigational, Nutraceutical

Phase 4

56-85-9

5961

Liver Extracts

Phase 4

bilirubin

Phase 4

635-65-4

5280352

Tissue Plasminogen Activator

Phase 4

N-Methylaspartate

Phase 4

Factor Xa Inhibitors

Phase 4

Anticoagulants

Phase 4

Serine Proteinase Inhibitors

Phase 4

Antithrombins

Phase 4

Antithrombin III

Phase 4

Sitagliptin Phosphate

Phase 4

654671-77-9

HIV Protease Inhibitors

Phase 4

Dipeptidyl-Peptidase IV Inhibitors

Phase 4

protease inhibitors

Phase 4

D-Alanine

Experimental, Nutraceutical

Phase 4

302-72-7, 338-69-2, 56-41-7

101757026 602 71080 5950

Serine

Investigational, Nutraceutical

Phase 4

56-45-1

5951

Radiation-Protective Agents

Phase 3

Protective Agents

Phase 3

Pancrelipase

Approved, Investigational

Phase 2

53608-75-6

8519

Soybean oil, phospholipid emulsion

Phase 2

Pancreatin

Phase 2

Mitogens

Phase 2

Cola

Phase 2

Gastrointestinal Agents

Phase 1, Phase 2

Antimetabolites

Phase 2

Hypolipidemic Agents

Phase 2

Anticholesteremic Agents

Phase 2

Lipid Regulating Agents

Phase 2

Cholestyramine Resin

Phase 2

Amoxicillin

Approved, Vet_approved

Phase 1

26787-78-0

33613

Levofloxacin

Approved, Investigational

Phase 1

100986-85-4

149096

Levoleucovorin

Approved, Experimental, Investigational

Phase 1

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Trimethoprim

Approved, Vet_approved

Phase 1

738-70-5

5578

Ofloxacin

Approved

Phase 1

82419-36-1

4583

Sulfamethoxazole

Approved

Phase 1

723-46-6

5329

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1

59-30-3

6037

Vaccines

Phase 1

Immunologic Factors

Phase 1

Antibiotics, Antitubercular

Phase 1

Anti-Bacterial Agents

Phase 1

Folic Acid Antagonists

Phase 1

Folate

Phase 1

Vitamin B9

Phase 1

Antiprotozoal Agents

Phase 1

Antiparasitic Agents

Phase 1

Interventional clinical trials:

(show top 50) (show all 123)

#	Name	Status	NCT ID	Phase	Drugs
1	The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome	Completed	NCT01974336	Phase 4	ursodeoxycholic acid
2	Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition	Completed	NCT02099084	Phase 4	Teduglutide;Placebo
3	A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN)	Completed	NCT03562130	Phase 4	Teduglutide
4	Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome	Completed	NCT02355743	Phase 4	rtPA lock therapy
5	Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project)	Completed	NCT01380366	Phase 4	Somatropin
6	Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition	Recruiting	NCT04344717	Phase 4	Apixaban single dose;Apixaban steady-state
7	An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome	Terminated	NCT00742157	Phase 4	Growth Hormone
8	The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome	Terminated	NCT02653131	Phase 4	Dipeptidyl peptidase-4 inhibitor
9	Safety and Efficacy of SMOFlipid in Patients Intolerant to Intralipid.	Withdrawn	NCT03054948	Phase 4	SMOFLipid;Standard therapy
10	Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition	Withdrawn	NCT01818648	Phase 4	Exenatide;Placebo
11	A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support	Completed	NCT02682381	Phase 3	Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
12	A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome	Completed	NCT00798967	Phase 3	teduglutide;placebo
13	A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)	Completed	NCT03690206	Phase 3	glepaglutide;Placebo
14	A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support	Completed	NCT02980666	Phase 3	Teduglutide
15	A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support	Completed	NCT01952080	Phase 3	teduglutide
16	A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301	Completed	NCT02954458	Phase 3	TED
17	Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome	Completed	NCT00169637	Phase 3	rhGH
18	A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome	Completed	NCT02340819	Phase 3	Teduglutide
19	A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome	Completed	NCT00930644	Phase 3	teduglutide
20	A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support	Completed	NCT03571516	Phase 3	Teduglutide
21	A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302	Completed	NCT03268811	Phase 3	Teduglutide
22	A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)	Completed	NCT00172185	Phase 3	teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
23	Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants	Completed	NCT02370251	Phase 2, Phase 3	Omegaven
24	A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support	Completed	NCT03663582	Phase 3	Teduglutide
25	A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome	Completed	NCT00081458	Phase 3	Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
26	Cholestasis Reversal: Efficacy of IV Fish Oil	Completed	NCT00910104	Phase 2, Phase 3	Omegaven®
27	An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004	Completed	NCT03596164	Phase 3	Teduglutide
28	A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021	Completed	NCT01560403	Phase 3	Teduglutide
29	A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003	Completed	NCT02949362	Phase 3	Teduglutide
30	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Apraglutide in Adult Subjects With Short Bowel Syndrome and Intestinal Failure (SBS-IF)	Recruiting	NCT04627025	Phase 3	apraglutide
31	A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)	Recruiting	NCT03905707	Phase 3	glepaglutide
32	A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation	Recruiting	NCT05027308	Phase 3	Teduglutide
33	An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.	Recruiting	NCT05018286	Phase 3	Apraglutide
34	A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (SBS)	Active, not recruiting	NCT04991311	Phase 3	Glepaglutide
35	A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial	Enrolling by invitation	NCT04881825	Phase 3	Glepaglutide
36	Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study	Terminated	NCT02266849	Phase 3	Loperamide;Placebo
37	A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection	Terminated	NCT02865122	Phase 2, Phase 3	NTRA-9620;Placebo
38	A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001	Withdrawn	NCT02246816	Phase 3	0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
39	A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals	Withdrawn	NCT02242656	Phase 3	Opium Tincture USP Deodorized
40	Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial	Unknown status	NCT00793195	Phase 2	Intralipid 20%;SMOFlipid 20%
41	A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS)	Unknown status	NCT04379856	Phase 1, Phase 2	NM-002
42	Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease	Unknown status	NCT01739517	Phase 2	Omegaven Therapy
43	A Phase 2 Trial Testing ZP1848 in Patients With SBS	Completed	NCT02690025	Phase 2	ZP1848
44	Use of Pancreatic Enzymes in Short Bowel Syndrome	Completed	NCT03097029	Phase 2	Pancreatic Enzyme
45	Diet/Growth Factor Mechanisms of Gut Adaptation	Completed	NCT00067860	Phase 2	recombinant human growth hormone
46	Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies	Completed	NCT01674478	Phase 2
47	A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen.	Completed	NCT03415594	Phase 1, Phase 2	FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue
48	A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency	Completed	NCT03408132	Phase 1, Phase 2	FE203799
49	Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure	Recruiting	NCT04604275	Phase 2	Sucrase
50	A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)	Recruiting	NCT04775706	Phase 2	HM15912 Active;Placebo

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Sources

Genetic Tests for Short Bowel Syndrome

Sources

Anatomical Context for Short Bowel Syndrome

Organs/tissues related to Short Bowel Syndrome:

MalaCards : Small Intestine, Kidney, Liver, Colon, Smooth Muscle, Bone, Bone Marrow

Sources

Publications for Short Bowel Syndrome

Articles related to Short Bowel Syndrome:

(show top 50) (show all 3859)

#	Title	Authors	PMID	Year
1	The use of GLP-2 and related growth factors in intestinal diseases. ⁵³ ⁶²	Yazbeck R...Howarth GS	20336592	2010
2	Medical management of pediatric intestinal failure. ⁵³ ⁶²	Kocoshis SA	20123270	2010
3	Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. ⁵³ ⁶²	Marier JF...Wallens J	19773525	2010
4	Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. ⁵³ ⁶²	Koopmann MC...Ney DM	19644131	2009
5	Short bowel syndrome: the role of GLP-2 on improving outcome. ⁵³ ⁶²	Wallis K...Gabe S	19474717	2009
6	Ghrelin does not predict adaptive hyperphagia in patients with short bowel syndrome. ⁵³ ⁶²	Compher CW...Metz DC	19176401	2009
7	Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? ⁵³ ⁶²	Yazbeck R...Abbott CA	19324585	2009
8	Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. ⁵³ ⁶²	Jeppesen PB...Mortensen PB	19707516	2009
9	Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. ⁵³ ⁶²	Jeppesen PB...Mortensen PB	19590736	2009
10	GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. ⁵³ ⁶²	Pereira-Fantini PM...Bines JE	18162829	2008
11	Review article: glucagon-like peptide 2--current applications and future directions. ⁵³ ⁶²	Wallis K...Forbes A	17217448	2007
12	Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. ⁵³ ⁶²	Martin GR...Sigalet DL	16830359	2006
13	Teduglutide for the treatment of short bowel syndrome. ⁵³ ⁶²	Ferrone M...Scolapio JS	16705029	2006
14	Glucagon-like peptide-2: update of the recent clinical trials. ⁵³ ⁶²	Jeppesen PB	16473060	2006
15	Dipeptidyl-peptidase IV in patients with short bowel syndrome. ⁵³ ⁶²	Farriol M...Delgado G	16169633	2005
16	Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. ⁵³ ⁶²	Jeppesen PB...Mortensen PB	16099790	2005
17	Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. ⁵³ ⁶²	Kitchen PA...Walters JR	15961680	2005
18	A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. ⁵³ ⁶²	Sigalet DL...Meddings JB	15937810	2005
19	Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. ⁵³ ⁶²	Martin GR...Sigalet DL	15388486	2005
20	Growth factors and trefoil peptides in gastrointestinal health and disease. ⁵³ ⁶²	Playford RJ...Mahmood A	15525545	2004
21	Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. ⁵³ ⁶²	Washizawa N...Ziegler TR	15568286	2004
22	Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. ⁵³ ⁶²	Thulesen J	14965320	2004
23	[Glucagon-like peptides--synthesis, biological actions and some clinical implications]. ⁵³ ⁶²	Otto Buczkowska E...Dworzecki T	15803906	2004
24	Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. ⁵³ ⁶²	Estall JL...Drucker DJ	14608100	2003
25	Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. ⁵³ ⁶²	Sham J...Sigalet DL	11987096	2002
26	Gut adaptation and the glucagon-like peptides. ⁵³ ⁶²	Drucker DJ	11839727	2002
27	Biological actions and therapeutic potential of the glucagon-like peptides. ⁵³ ⁶²	Drucker DJ	11832466	2002
28	Enhancement of intestinal growth and repair by growth factors. ⁵³ ⁶²	Howarth GS...Shoubridge CA	11757811	2001
29	Cholecystokinin (CCK) secretion in patients with severe short bowel syndrome (SSBS). ⁵³ ⁶²	Ling PR...Bistrian BR	11330425	2001
30	Glucagon-like peptide 2. ⁵³ ⁶²	Drucker DJ	11297614	2001
31	Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. ⁵³ ⁶²	Johnson WF...Farrell CL	10653491	2000
32	Epidermal growth factor and the short bowel syndrome. ⁵³ ⁶²	Thompson JS	10483910	1999
33	Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin. ⁵³ ⁶²	Litvak DA...Townsend CM	10482697	1999
34	Clinical use of growth hormone and glutamine in short bowel syndrome. ⁵³ ⁶²	Cukier C...Pinotti HW	10488599	1999
35	Epidermal growth factor stimulates the recovery of glucose absorption after small bowel transplantation. ⁵³ ⁶²	Kato Y...Hioki K	9878331	1998
36	Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome. ⁵³ ⁶²	Alavi K...Schwartz MZ	9856891	1998
37	Epidermal growth factor selectively enhances functional enterocyte adaptation after massive small bowel resection. ⁵³ ⁶²	Dunn JC...Ashley SW	9070188	1997
38	Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. ⁵³ ⁶²	Seydel AS...Sax HC	8862081	1996
39	Epidermal growth factor improves intestinal adaptation during somatostatin administration in vivo. ⁵³ ⁶²	Liu CD...McFadden DW	8661191	1996
40	Potential indications for octreotide in gastroenterology: summary of workshop. ⁵³ ⁶²	Burroughs AK...Malagelada R	8359570	1993
41	Somatostatin and its analogs in the short bowel syndrome. ⁵³ ⁶²	Rosen GH	1363486	1992
42	Aminoguanidine blocks intestinal diamine oxidase (DAO) activity and enhances the intestinal adaptive response to resection in the rat. ⁵³ ⁶²	Rokkas T...Dowling RH	2124566	1990
43	Generation of Porcine Ileum Through Spring-Mediated Mechanical Distraction. ⁶²	Rafeeqi TA...Dunn JCY	36037614	2022
44	In Vivo Intestinal Research Using Organoid Transplantation. ⁶²	Sugimoto S...Sato T	36450523	2022
45	Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects. ⁶²	Agersnap MA...Berner-Hansen M	36323988	2022
46	Motility disorders in children with intestinal failure: a national tertiary referral center experience. ⁶²	Eshel Fuhrer A...Sukhotnik I	36114865	2022
47	Gastroschisis: a systematic review of diagnosis, prognosis and treatment. ⁶²	Ferreira RG...Ruano R	33899664	2022
48	The role of gastrostomy feeding during intestinal rehabilitation for children with short bowel syndrome. ⁶²	Eshel Fuhrer A...Sukhotnik I	36462084	2022
49	Crohn's disease and short bowel syndrome. ⁶²	Pinton P	35767069	2022
50	[WAYS TO SOLVE THE PROBLEM OF HOME PARENTERAL NUTRITION IN PATIENTS WITH SHORT BOWEL SYNDROME]. ⁶²	Kuzmina TN...Knyazev OV	36385073	2022

Sources

Genes for Short Bowel Syndrome

Genes related to Short Bowel Syndrome (0 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CLMP	CXADR Like Membrane Protein	Protein Coding	33.66	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
2	GCG	Glucagon	Protein Coding	27.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19474717 18162829 16705029 (more) 15803906 19324585 14608100 19644131 11839727 20336592 15388486 10482697 16099790 15568286 11757811 19707516 16830359 14965320 15961680 15525545 20123270 11832466 19590736 11297614 16473060 19773525 17217448
3	FLNA	Filamin A	Protein Coding	22.09	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
4	PYY	Peptide YY	Protein Coding	21.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19176401
5	SST	Somatostatin	Protein Coding	20.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1363486 8661191 8359570 (more) 8862081
6	EGF	Epidermal Growth Factor	Protein Coding	19.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11987096 10483910 15937810 (more) 9070188 15961680 9878331 15525545 20123270
7	FGF7	Fibroblast Growth Factor 7	Protein Coding	19.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10653491 11757811 15568286
8	CCK	Cholecystokinin	Protein Coding	17.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11330425
9	NTS	Neurotensin	Protein Coding	17.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10482697
10	HGF	Hepatocyte Growth Factor	Protein Coding	16.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9856891 11757811
11	GLP2R	Glucagon Like Peptide 2 Receptor	Protein Coding	15.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	AOC1	Amine Oxidase Copper Containing 1	Protein Coding	15.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2124566
13	GH1	Growth Hormone 1	Protein Coding	14.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10488599
14	SLC15A1	Solute Carrier Family 15 Member 1	Protein Coding	14.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	GAST	Gastrin	Protein Coding	14.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	IGF1	Insulin Like Growth Factor 1	Protein Coding	13.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	IL6	Interleukin 6	Protein Coding	13.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	13.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	SLC9A3	Solute Carrier Family 9 Member A3	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	TTR	Transthyretin	Protein Coding	13.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	LEP	Leptin	Protein Coding	12.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	PTH	Parathyroid Hormone	Protein Coding	12.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	SLC9A2	Solute Carrier Family 9 Member A2	Protein Coding	12.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	VIP	Vasoactive Intestinal Peptide	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	IL1B	Interleukin 1 Beta	Protein Coding	12.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Short Bowel Syndrome

Sources

Expression for Short Bowel Syndrome

Search GEO for disease gene expression data for Short Bowel Syndrome.

Sources

Pathways for Short Bowel Syndrome

Pathways related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 23)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.47	SST PYY NTS GLP2R GHRL GCG
2	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	13.28	SST PYY NTS GLP2R GHRL GCG
3	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.2	EGF FGF7 GH1 HGF IGF1 IL6
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.15	IL6 IGF1 HGF GH1 FLNA FGF7
5	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	12.96	IL6 IGF1 HGF GH1 FGF7 EGF
6	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	12.92	IL6 IGF1 HGF GH1 FGF7 EGF
7	Signal Transduction ⁶⁶	12.88	SST PYY NTS IL6 IGF1 HGF
8	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.78	EGF FGF7 GH1 HGF IGF1 IL6
9	Malignant pleural mesothelioma ⁷⁴	12.53	IL6 IGF1 HGF FGF7 EGF
10	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.47	IL6 IGF1 HGF GH1 FGF7 EGF
11	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.46	IL6 IGF1 HGF GH1 FGF7 EGF
12	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.2	IL6 IGF1 HGF GH1 FGF7 EGF
13	Focal adhesion ⁷⁴	12.16	IGF1 HGF FLNA EGF
14	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.04	IGF1 GHRL GH1 GCG
15	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.77	IL6 IGF1 EGF
16	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.68	IL6 IGF1 HGF FGF7 EGF
17	Burn wound healing ⁷⁴	11.65	IL6 HGF EGF
18	G-protein signaling_RhoA regulation pathway ²²	11.49	EGF FGF7 GH1 HGF IGF1 IL6
19	Pluripotent stem cell differentiation pathway ⁷⁴	11.24	IL6 IGF1 HGF EGF
20	Lung fibrosis ⁷⁴	11.15	IL6 IGF1 HGF FGF7 EGF
21	Extracellular vesicles in the crosstalk of cardiac cells ⁷⁴	10.92	IL6 IGF1 EGF
22	G-protein signaling_Rap2B regulation pathway ²²	10.84	IL6 IGF1 HGF GH1 FGF7 EGF
23	SCFA and skeletal muscle substrate metabolism ⁷⁴	10.33	PYY GCG

Sources

GO Terms for Short Bowel Syndrome

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.1	AOC1 CCK EGF FGF7 GAST GCG
2	extracellular region	GO:0005576	9.83	AOC1 CCK EGF FGF7 FLNA GAST
3	brush border	GO:0005903	9.63	SLC9A3 SLC15A1 FLNA

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.18	IL6 IGF1 HGF GHRL GCG FLNA
2	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.86	EGF GH1 HGF IGF1
3	epithelial to mesenchymal transition	GO:0001837	9.85	IGF1 HGF FLNA
4	positive regulation of MAPK cascade	GO:0043410	9.85	IL6 IGF1 HGF GHRL EGF
5	epithelial cell proliferation	GO:0050673	9.83	HGF FGF7 EGF
6	regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling	GO:0060665	9.62	HGF FGF7
7	myoblast proliferation	GO:0051450	9.43	IGF1 HGF FGF7
8	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.36	IL6 IGF1 HGF GH1 FGF7 EGF

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.73	IL6 IGF1 HGF GH1 FGF7 EGF
2	neuropeptide hormone activity	GO:0005184	9.63	PYY NTS CCK
3	hormone activity	GO:0005179	9.55	TTR SST PYY IGF1 GHRL GH1